Login
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

kerostx.com

What Do They Do?

Develops protein-based drug candidates for people with neuromuscular diseases and patients with low blood cell counts, including those with myelodysplastic syndromes and myelofibrosis.

How Do They Make Money?

Partners pay for rights to develop, manufacture and sell drug candidates through upfront license payments and development milestones; Keros may also receive sales milestones and royalties. It also earns service revenue by providing research, development, manufacturing and transition services, with clinical supplies paid for when ready to ship.

revenue
SegmentShareRevenue
License revenue
84%
Service revenue
16%

Who Are Their Customers?

Takeda and Hansoh license elritercept rights in their respective territories; Keros also supplies clinical trial materials and provides related services to these partners.

Do Revenues Turn Into Profits?

Yes. It kept 36 cents of every revenue dollar as net income in FY2025 and turned 43 cents into free cash flow.

Operating income, FY2025
28% of revenue
▲ Turned profitable vs FY2024 (−$210.8M)
Net income, FY2025
36% of revenue
▲ Turned profitable vs FY2024 (−$187.4M)
Free cash flow, FY2025
43% of revenue
▲ Turned profitable vs FY2024 (−$162.8M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +183%
vs $14.1M in Q3 FY2025
Net income
▲ Turned profitable
vs −$7.3M in Q3 FY2025
License revenue share of revenue vs 70.8% in Q3 FY2025
  • Jul 22, 2026 CFO Keith Regnante resigned; Annita Tanini became interim finance officer Regnante's resignation took effect August 3, 2026; the company began searching for a new CFO.

Growing. Revenue grew 12.1x in 4 years, from $20.1M in FY2021 to $243.9M in FY2025, about 87% a year.

Broader disease focus The earlier report centered its pipeline on blood, pulmonary and cardiovascular disorders, including functional iron deficiency and pulmonary arterial hypertension. The latest report also describes programs for neuromuscular diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis.

Pipeline focus The earlier report described programs for functional iron deficiency and pulmonary and cardiovascular disorders. The latest report instead emphasizes treatments for neuromuscular diseases and low blood cell counts.

Revenue over time
License revenue Service revenue Service and other revenue
$250M$125M$0

Who Do They Compete With?

Competes with PTC Therapeutics, Catalyst Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku, REGENXBIO, Solid Biosciences, Avidity Biosciences, Wave Life Sciences, Dyne Therapeutics, Edgewise Therapeutics, Satellos Bioscience, Otsuka Pharmaceutical, Novartis, Genervon Biopharmaceuticals, Kyntra Bio, Astellas Pharma, Merck, Bristol-Myers Squibb, Disc Medicine, and Geron

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support